A2691
Anti-Human IgA (α-chain specific)−Agarose antibody produced in goat
affinity isolated antibody, adsorbed with mouse and rat IgG
Synonym(s):
Goat Anti-Human IgA
Sign Into View Organizational & Contract Pricing
Select a Size
2 ML
£205.00
5 ML
£396.00
All Photos(1)
Select a Size
Change View
2 ML
£205.00
5 ML
£396.00
About This Item
Recommended Products
biological source
goat
Quality Level
conjugate
agarose conjugate
antibody form
affinity isolated antibody
antibody product type
secondary antibodies
clone
polyclonal
form
PBS suspension
species reactivity
human
should not react with
rat, mouse
capacity
3-4 mg/mL binding capacity (human IgA)
storage temp.
2-8°C
target post-translational modification
unmodified
Related Categories
General description
Binding Capacity: One mL of antibody binds 3-4 mg human IgA. Elution Capacity is 2-4 mg/mL.
IgA antibody plays an essential role in mucosal immunity. It has shown to bind immunogens/pathogens to restrict them from entering the mucosal membrane. The Anti-Human IgA (α-chain specific) product increases sensitivity to human IgA without cross-reactivity to other substances. Offering minimal interspecies cross reactivity to mouse or a rat, making it ideal for use in screening antibodies produced by a hybridoma cells containing a mouse or a rat immunoglobulins.
Immunogen
IgA produced from transformed cell line of human Epstein-Barr virus.
Application
Affinity chromatography using anti-human IgA antibody linked to agarose was performed to purify proteins from 2E9IgA1 transfectant cells.
Anti-Human IgA (α-chain specific)-Agarose antibody produced in goat has been used in affinity chromatography and quantitative enzyme linked immunosorbent assay (ELISA).
Physical form
Suspension in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Storage Class Code
10 - Combustible liquids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Choose from one of the most recent versions:
Certificates of Analysis (COA)
Lot/Batch Number
Don't see the Right Version?
If you require a particular version, you can look up a specific certificate by the Lot or Batch number.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Florian Erger et al.
Proceedings of the National Academy of Sciences of the United States of America, 120(22), e2211087120-e2211087120 (2023-05-22)
Mutations in genes encoding molecular chaperones can lead to chaperonopathies, but none have so far been identified causing congenital disorders of glycosylation. Here we identified two maternal half-brothers with a novel chaperonopathy, causing impaired protein O-glycosylation. The patients have a
Poor ex vivo induction of T-cell responses to idiotype or tumor cell lysate-pulsed autologous dendritic cells in advanced pre-treated multiple myeloma
Garderet L, et al.
Leukemia & Lymphoma, 47(7), 1340-1347 (2006)
M Kristen Demoruelle et al.
Arthritis research & therapy, 23(1), 163-163 (2021-06-08)
Mucosal sites are hypothesized to play a role in the development of rheumatoid arthritis (RA). Since serum anti-peptidylarginine deiminase (PAD)4 antibodies, including a subset that cross-react with PAD3 (PAD3/4), are specific for RA and associate with severe disease, we sought
Yuanyi Yue et al.
Frontiers in immunology, 12, 758040-758040 (2022-02-11)
The tumor microenvironment (TME) plays an important role in the pathogenesis of many cancers. We aimed to screen the TME-related hub genes of colorectal adenoma (CRAD) and identify possible prognostic biomarkers. The gene expression profiles and clinical data of 464
Yasuyuki Matsumoto et al.
Science advances, 8(43), eabm8783-eabm8783 (2022-10-29)
The underlying pathology of immunoglobulin A (IgA) nephropathy (IgAN), the most common glomerulonephritis worldwide, is driven by the deposition of immune complexes containing galactose-deficient IgA1 [Tn(+)IgA1] in the glomerular mesangium. Here, we report that novel anti-Tn circulating immune complexes (anti-Tn
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service
